ITM Isotope Technologies Munich has opened a new manufacturing plant in Neufahrn, Germany, specifically designed to produce lutetium-177 (Lu-177) for use in cancer therapies.
Once the new production facility is fully operational, ITM will increase its manufacturing capacity tenfold to supply clinics, pharmaceutical partners, and its own drug pipeline, the company said. Lu-177 is used to make radiopharmaceuticals used for cancer treatment, such as Lu-177 PSMA-617 (Pluvicto).
The first test runs of the facility are set to begin within the next few months, with final official approvals expected in the coming year, ITM said.
